Change of public accounting firm

Renalytix PLC

25 June 2024

 

Renalytix plc

("Renalytix" or the "Company")

Change of public accounting firm

LONDON and NEW YORK, 25 June 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the appointment of CohnReznick LLP as the Company's US independent registered public accounting firm for the fiscal year ended June 30, 2024.

On June 21, 2024, Ernst & Young LLP, was informed of their dismissal as the Company's independent registered public accounting firm with such dismissal to be effective as of June 18, 2024.

James McCullough, CEO of Renalytix plc, commented: "We will continue to look for opportunities to improve cost efficiencies and grow revenue as they become available. We are reducing administrative expenses to allocate more resources into sales and marketing, which is proving effective."

For further information, please contact:

Renalytix plc	www.renalytix.com
James McCullough, CEO	Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)	Tel: [phone]
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea
Investec Bank plc (Joint Broker)	Tel: [phone]
Gary Clarence / Shalin Bhamra
Walbrook PR Limited Paul McManus / Alice Woodings / Charlotte Edgar	Tel: [phone] or [e-mail] Mob: [phone] / 07884 664 686
CapComm Partners
Peter DeNardo	Tel: [phone] or [e-mail]

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

END